Adaptive and innate immunity
Our ultimate vision is to prevent and provide cures for cancer in all its forms. Because no single intervention is likely to achieve this goal, we seek to comprehensively understand the disease, its complexities and its impact on patients.
We have the broadest and most diverse pipeline in oncology with more than 20 immunotherapy molecules. Since 2011, we have introduced 18 oncology medicines. All our efforts are linked by exploring therapeutic combinations and by a commitment to pursuing personalized medicines.
If you have an opportunity for collaboration or an interesting technology, or if you have an asset in one of our areas of interest, we would like to hear from you.